- Home
- FTRA vs VNDA Comparison
FTRA vs VNDA Comparison
Compare FTRA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTRA | VNDA |
|---|---|---|
| Founded | 2026 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.5M | 301.1M |
| IPO Year | 2026 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FTRA | VNDA |
|---|---|---|
| Price | $9.87 | $3.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 36.6K | ★ 814.3K |
| Earning Date | N/A | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | N/A | $35.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $9.85 | $3.88 |
| 52 Week High | $9.95 | $9.91 |
Technical Indicators
Market Signals| Indicator | FTRA | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 25.90 |
| Support Level | $9.86 | N/A |
| Resistance Level | $9.88 | $5.37 |
| Average True Range (ATR) | 0.01 | 0.19 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 50.00 | 9.15 |
Price Performance
Historical ComparisonAbout FTRA FutureCorp Space Acquisition 1 Class A Ordinary Shares
FutureCorp Space Acquisition 1 is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.